Want to see UNCY full AI Analyst Report?
Unicycive Therapeutics (UNCY) Ratios
Unicycive Therapeutics Ratios
UNCY's free cash flow for Q2 2026 was $-7.60M. For the 2026 fiscal year, UNCY's free cash flow was increased by $1.00K and operating cash flow was $-7.60M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Mar 25 | Dec 23 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.59 | 1.28 | 0.76 | 0.81 | 8.75 |
| Quick Ratio | 2.59 | 1.28 | 0.76 | 0.81 | 8.75 |
| Cash Ratio | 1.54 | 1.08 | 0.55 | 0.14 | 7.88 |
| Solvency Ratio | -1.37 | -1.50 | -1.68 | -5.45 | -4.43 |
| Operating Cash Flow Ratio | -1.65 | -1.18 | -1.04 | -4.77 | -2.74 |
| Short-Term Operating Cash Flow Coverage | -381.91 | -310.60 | -1015.72 | -340.24 | -198.86 |
| Net Current Asset Value | $ 30.02M | $ 6.71M | $ -4.60M | $ -640.00K | $ 16.15M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.02 | 0.06 | 0.07 | 0.02 |
| Debt-to-Equity Ratio | 0.01 | 0.10 | -0.21 | -0.43 | 0.02 |
| Debt-to-Capital Ratio | 0.01 | 0.09 | -0.27 | -0.76 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.63 | 4.26 | -3.73 | -6.05 | 1.14 |
| Debt Service Coverage Ratio | -169.36 | -222.27 | -301.78 | -344.06 | -14.27 |
| Interest Coverage Ratio | -415.73 | -452.35 | -253.34 | -3008.67 | -14.29 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Interest Debt Per Share | 0.02 | 0.13 | 0.36 | 0.14 | 0.82 |
| Net Debt to EBITDA | 1.12 | 0.70 | 0.29 | 0.01 | 1.73 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | -4512.89% | -1898.21% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | -4470.81% | -1881.28% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | -3077.63% | -1898.21% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | -4525.04% | -1898.84% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | -4525.04% | -1898.84% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | -4525.04% | -1898.84% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 89.97% | 114.36% | 147.03% | 100.03% | 111.59% |
| Return on Assets (ROA) | -54.04% | -115.98% | -215.24% | -640.81% | -53.44% |
| Return on Equity (ROE) | -87.94% | -494.27% | 801.89% | 3875.11% | -60.77% |
| Return on Capital Employed (ROCE) | -97.75% | -425.50% | 621.42% | 3873.82% | -53.95% |
| Return on Invested Capital (ROIC) | -97.11% | -391.48% | 692.93% | 6812.08% | -53.37% |
| Return on Tangible Assets | -54.04% | -115.98% | -215.24% | -640.81% | -53.44% |
| Earnings Yield | -28.97% | -69.06% | -143.40% | -222.09% | -41.65% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 1.90 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.85 | 5.47 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.05 | 0.34 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | -0.28 | 0.12 | 0.00 |
| Cash Conversion Cycle | -192.07 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 192.07 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.97 | -4.27 | -7.45 | -10.39 | -4.94 |
| Free Cash Flow Per Share | -1.97 | -4.28 | -7.46 | -10.40 | -4.96 |
| Dividend Paid and CapEx Coverage Ratio | -1304.88 | -24.49 | -1523.58 | -7825.50 | -198.86 |
| Capital Expenditure Coverage Ratio | -1304.88 | -396.88 | -1523.58 | -7825.50 | -198.86 |
| Operating Cash Flow Coverage Ratio | -157.37 | -36.97 | -22.54 | -77.87 | -17.21 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | -27.09 | -16.46 | 0.00 |
| Free Cash Flow Yield | -34.19% | -53.86% | -85.89% | -192.51% | -24.10% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.46 | -1.42 | -0.70 | -0.45 | -2.40 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 31.56 | 8.55 | 0.00 |
| Price-to-Book (P/B) Ratio | 3.04 | 7.16 | -5.59 | -17.45 | 1.46 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.92 | -1.86 | -1.16 | -0.52 | -4.15 |
| Price-to-Operating Cash Flow Ratio | -2.93 | -1.86 | -1.17 | -0.52 | -4.17 |
| Price-to-Earnings Growth (PEG) Ratio | 0.05 | -0.00 | -0.10 | 0.01 | -0.00 |
| Enterprise Value Multiple | -2.42 | -0.77 | -0.41 | -0.44 | -0.83 |
| Enterprise Value | 62.67M | 27.82M | 12.41M | 7.88M | 7.81M |
| EV to EBITDA | -2.42 | -0.77 | -0.41 | -0.44 | -0.83 |
| EV to Sales | 0.00 | 0.00 | 18.39 | 8.28 | 0.00 |
| EV to Free Cash Flow | -2.00 | -0.97 | -0.68 | -0.50 | -1.35 |
| EV to Operating Cash Flow | -2.00 | -0.97 | -0.68 | -0.50 | -1.35 |
| Tangible Book Value Per Share | 1.90 | 1.11 | -1.55 | -0.31 | 14.12 |
| Shareholders’ Equity Per Share | 1.90 | 1.11 | -1.55 | -0.31 | 14.12 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.28 | 0.63 | 0.00 |
| Net Income Per Share | -1.67 | -5.48 | -12.45 | -11.99 | -8.58 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.07 |
| Research & Development to Revenue | 0.00 | 0.00 | 19.11 | 13.08 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 12.66 | 6.91 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 2.62 | 1.10 | 0.00 |
| Income Quality | 1.18 | 0.78 | 0.60 | 0.87 | 0.58 |
Currency in USD